



## Press release

### **TxCell to present at the 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference on September 13, 2016**

**Valbonne, France, September 5, 2016 – TxCell SA (FR0010127662 – TXCL)**, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces it will be featured as a presenting company at the 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 in New York. Stéphane Boissel, CEO of TxCell, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live. The webcast replay will remain available for 90 days following the live presentation.

#### **Presentation details**

- Date and time: Tuesday, September 13 at 9:35-10:00 AM (Eastern Time)
- Location: Louis (4<sup>th</sup> Floor) ; Lotte New York Palace Hotel in New York City
- Webcast link: <http://wsw.com/webcast/rrshq26/txcl.pa>

#### **Next events**

Over the next couple of months, TxCell will attend a number of financial, business and scientific conferences, as shown below:

##### **Financial and business conferences**

Oct 5-7, 2016	Cell & Gene Meeting on the Mesa	La Jolla (US)
Oct 5-6, 2016	European Large & Midcap Event	Paris (France)
Oct 26, 2016	GGs Equity Forum	Heilbronn (Germany)

##### **Scientific conferences**

Sept 7-8, 2016	Cell & Gene Therapy Manufacturing Conference	London (UK)
Sept 21-22, 2016	Phacilitate Leaders Forum (Cell & Gene Therapy Europe and Immunotherapy Europe)	Berlin (Germany)
Sept 30-Oct 2, 2016	ISCT North America Regional Meeting	Memphis (US)
Oct 10-11, 2016	Adoptive T-cell Therapy Summit Europe 2016	London (UK)
Oct 15-19, 2016	United European Gastroenterology Week 2016	Vienna (Austria)
Oct 18-21, 2016	European Society of Gene and Cell Therapy (ESGCT) Annual Meeting 2016	Firenze (Italy)

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated.

TxCell is developing two proprietary technology platforms, ASTrIA and ENTrIA. ASTrIA is composed of autologous antigen-specific Type 1 Tregs. Ovasave®, TxCell's lead drug-candidate originating from the ASTrIA platform, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. ENTrIA is composed of Chimeric Antigen Receptor engineered FoxP3+ regulatory T cells (CAR-Treg). In this area, TxCell is pursuing two CAR-Treg development programs in collaboration with leading European research institutions: one targeting Lupus Nephritis with Ospedale San Raffaele in Milan and the other targeting Bullous Pemphigoid with the Lübeck Institute of Experimental Dermatology.

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 50 employees.

## Contacts

### **TxCell**

Caroline Courme  
IR & Communication Director  
Tel: +33(0) 4 97 21 83 00  
[caroline.courme@txcell.com](mailto:caroline.courme@txcell.com)

### **Image Box – Press relations**

Neil Hunter / Michelle Boxall  
Tel: +44(0) 20 8943 4685  
[neil.hunter@imageboxpr.co.uk](mailto:neil.hunter@imageboxpr.co.uk)  
[michelle.boxall@imageboxpr.co.uk](mailto:michelle.boxall@imageboxpr.co.uk)

### **NewCap – Investor relations**

Julien Perez / Pierre Laurent  
Tel: +33 (0)1 44 71 98 52  
[txcell@newcap.eu](mailto:txcell@newcap.eu)

## Disclaimer

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered *per se* as historical facts, including TxCell's ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company's products, which may not succeed, or in the delivery of TxCell's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affect TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 "Risk factors" of the 2015 *document de référence* approved by the AMF on May 24, 2016 under number R.16-048. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be "accurate, precise and fairly presented"), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.